摘要
目的研究分析硝苯地平缓释片治疗高血压合并糖尿病的临床疗效。方法140例高血压合并糖尿病患者,随机分为研究组和对照组,每组70例。对照组接受氯沙坦治疗,研究组接受硝苯地平缓释片治疗。比较两组治疗前后血压(收缩压、舒张压)和血糖[空腹血糖、餐后2 h血糖、糖化血红蛋白(HbA1c)]水平。结果研究组患者治疗前的收缩压、舒张压、空腹血糖、餐后2 h血糖、糖化血红蛋白水平分别为(160.08±6.65)mm Hg(1 mm Hg=0.133 kPa)、(115.31±6.25)mm Hg、(9.28±1.81)mmol/L、(11.08±1.25)mmol/L、(8.31±1.25)%,治疗后分别为(125.63±5.62)mm Hg、(81.32±8.45)mm Hg、(7.32±0.14)mmol/L、(9.13±0.62)mmol/L、(7.02±1.45)%;对照组患者治疗前的收缩压、舒张压、空腹血糖、餐后2 h血糖、糖化血红蛋白水平分别为(160.39±6.62)mm Hg、(116.04±6.37)mm Hg、(9.82±1.71)mmol/L、(11.39±0.62)mmol/L、(8.04±1.37)%,治疗后分别为(148.45±7.52)mm Hg、(104.62±7.52)mm Hg、(7.75±0.53)mmol/L、(9.75±0.52)mmol/L、(7.62±0.52)%。治疗前,两组患者的收缩压、舒张压、空腹血糖、餐后2 h血糖、糖化血红蛋白水平比较差异均无统计学意义(P>0.05);治疗后,两组患者的收缩压、舒张压、空腹血糖、餐后2 h血糖、糖化血红蛋白水平均低于治疗前,研究组患者的收缩压、舒张压、空腹血糖、餐后2 h血糖、糖化血红蛋白水平均显著低于对照组,差异有统计学意义(P<0.05)。结论高血压合并糖尿病患者实施硝苯地平缓释片治疗的临床效果更加显著,值得推广。
Objective To study and analyze the clinical efficacy of nifedipine sustained-release tablets in the treatment of hypertension complicated with diabetes mellitus.Methods A total of 140 patients with hypertension and diabetes mellitus were randomly divided into research group and control group,with 70 cases in each group.The control group received losartan treatment,and the research group received nifedipine sustainedrelease tablets treatment.The blood pressure(systolic blood pressure,diastolic blood pressure)and blood glucose[fasting blood glucose,2 h postprandial blood glucose,and glycosylated hemoglobin(HbA1 c)]before and after treatment were compared between the two groups.Results In the research group,the systolic blood pressure,diastolic blood pressure,fasting blood glucose,2 h postprandial blood glucose,and glycosylated hemoglobin were(160.08±6.65)mm Hg(1 mm Hg=0.133 kPa),(115.31±6.25)mm Hg,(9.28±1.81)mmol/L,(11.08±1.25)mmol/L,(8.31±1.25)% before treatment,and(125.63±5.62)mm Hg,(81.32±8.45)mm Hg,(7.32±0.14)mmol/L,(9.13±0.62)mmol/L,(7.02±1.45)% after treatment;in the control group,the systolic blood pressure,diastolic blood pressure,fasting blood glucose,2 h postprandial blood glucose,and glycosylated hemoglobin were(160.39±6.62)mm Hg,(116.04±6.37)mm Hg,(9.82±1.71)mmol/L before treatment,and(148.45±7.52)mm Hg,(104.62±7.52)mm Hg,(7.75±0.53)mmol/L,(9.75±0.52)mmol/L,(7.62±0.52)% after treatment.Before treatment,the differences in systolic blood pressure,diastolic blood pressure,fasting blood glucose,2 h postprandial blood glucose and glycosylated hemoglobin between the two groups were not statistically significant(P>0.05).After treatment,the systolic blood pressure,diastolic blood pressure,fasting blood glucose,2 h postprandial blood glucose,and glycosylated hemoglobin in both groups were lower than those in this group before treatment,and the research group was significantly lower than the control group.All the differences were statistically significant(P<0.05).Conclusion The clinical effect of nifedipine sustained-release tablets for patients with hypertension and diabetes mellitus is more significant and worthy of promotion.
作者
曹百一
CAO Bai-yi(Department of Pharmacy,Liaoyang Hospital of Traditional Chinese Medicine,Liaoyang 111000,China)
出处
《中国现代药物应用》
2022年第2期132-134,共3页
Chinese Journal of Modern Drug Application
关键词
高血压
糖尿病
硝苯地平缓释片
临床疗效
Hypertension
Diabetes mellitus
Nifedipine sustained-release tablets
Clinical efficacy
